Naclerio R M, Meier H L, Kagey-Sobotka A, Norman P S, Lichtenstein L M
Arch Otolaryngol. 1984 Jan;110(1):25-7. doi: 10.1001/archotol.1984.00800270029008.
A novel human in vivo model of intranasal challenge with antigen is used to demonstrate the effectiveness of a topical antirelease drug. Previous experimentation has established a highly significant correlation between the physiologic response of sneezing, which occurs after insufflation of antigen into the nose of allergic individuals, and the recovery of putative mast cell mediators: histamine, tosyl arginine methyl ester (TAME)-esterase(s), and prostaglandin D2- Azatadine base, a tricyclic antihistamine, which also inhibits mediator release in vitro, applied prior to antigen administration not only reduces the clinical symptom of sneezing but simultaneously reduces the concentration of the inflammatory mediator, TAME-esterase(s), recovered from nasal washes. To our knowledge, this is the first observation that an antirelease drug can stop mediator release in vivo in the nose.
一种新型的抗原鼻内激发人体体内模型被用于证明局部抗释放药物的有效性。先前的实验已证实，在将抗原注入过敏个体鼻腔后出现的生理反应打喷嚏，与假定的肥大细胞介质（组胺、甲苯磺酰精氨酸甲酯（TAME）酯酶和前列腺素D2）的释放之间存在高度显著的相关性。三环抗组胺药阿扎他定碱，它在体外也能抑制介质释放，在给予抗原之前应用，不仅能减轻打喷嚏的临床症状，同时还能降低从鼻腔冲洗液中回收的炎症介质TAME酯酶的浓度。据我们所知，这是首次观察到抗释放药物能在体内阻止鼻腔内的介质释放。
